4//SEC Filing
THURMAN RANDY H 4
Accession 0001213900-22-060782
CIK 0001733413other
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 5:20 PM ET
Size
9.1 KB
Accession
0001213900-22-060782
Insider Transaction Report
Form 4
THURMAN RANDY H
Director
Transactions
- Exercise/Conversion
Common Stock
2022-09-29$2.50/sh+40,255$100,638→ 40,255 total - Exercise/Conversion
Stock Options (Right to Buy)
2022-09-29−40,255→ 84,670 totalExercise: $2.50From: 2019-04-11Exp: 2029-04-11→ Common Stock (40,255 underlying) - Sale
Common Stock
2022-09-29$4.29/sh−40,255$172,694→ 0 total
Footnotes (2)
- [F1]The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).
- [F2]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
Documents
Issuer
TFF Pharmaceuticals, Inc.
CIK 0001733413
Entity typeother
Related Parties
1- filerCIK 0001204059
Filing Metadata
- Form type
- 4
- Filed
- Sep 29, 8:00 PM ET
- Accepted
- Sep 30, 5:20 PM ET
- Size
- 9.1 KB